Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, this improvement lasted for up to 140 days after the single dose.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a proof-of-concept study with a single application of the anti-IL-33 antibody etokimab (ANB020) in 12 patients with moderate or severe AD, 33% of patients reached the primary end point EASI75 and 83% reached EASI50 (ref.68).”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Etokimab inhibited direct, as well as CXCR1-dependent, neutrophil migration in vitro.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundSelf-citationγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731 · cited 1×
“In murine models, either IL-33 or TSLP alone is sufficient to promote the development of AD-like inflammation (39).”
BackgroundSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G
Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.-P., & Cayrol, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115884109 · Cited by 594 · cited 1×
“Furthermore, IL-33 can be cleaved into active forms by neutrophil elastase and cathepsin G (21), implicating an inflammatory cycle.”
BackgroundThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546 · cited 1×
“The soluble IL-33 decoy receptor soluble ST2 (sST2) has been used in treating allergic diseases in model systems (27).”
Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection
Alves-Filho, J. C., Sônego, F., Souto, F. O., Freitas, A., Verri, W. A., Auxiliadora-Martins, M., Basile-Filho, A., McKenzie, A. N., Xu, D., Cunha, F. Q., et al. (2010) · Nature Medicine · doi:10.1038/nm.2156 · Cited by 486 · cited 4×
“IL-33 is known to modulate the inhibitory effects of bacterial infection on the neutrophil IL-8 receptor CXCR2 in animal models, but whether IL-33 can modulate IL-8 effects in human inflammation in vivo has not been studied, nor whether there is an impact of IL-33 on the other known IL-8 receptor, CXCR1 (17, 18, 22).”
BackgroundInfluentialKondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N., Hoshino, T., Fujimoto, J., & Nakanishi, K. (2008) · International Immunology · doi:10.1093/intimm/dxn037 · Cited by 478 · cited 1×
“IL-33 administration to mice induces type 2 cytokines, serum immunoglobulin E (IgE), eosinophilia, T helper 2 and group 2 innate lymphoid cell (ILC2) accumulation and activation, epithelial cell hyperplasia, excessive mucus production, and smooth muscle contraction (12, 13).”
BackgroundBarlow, J. L., Bellosi, A., Hardman, C. S., Drynan, L. F., Wong, S. H., Cruickshank, J. P., & McKenzie, A. N. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.041 · Cited by 474 · cited 1×
“IL-33 administration to mice induces type 2 cytokines, serum immunoglobulin E (IgE), eosinophilia, T helper 2 and group 2 innate lymphoid cell (ILC2) accumulation and activation, epithelial cell hyperplasia, excessive mucus production, and smooth muscle contraction (12, 13).”
BackgroundSelf-citationIL-33 exacerbates antigen-induced arthritis by activating mast cells
Xu, D., Jiang, H.-R., Kewin, P., Li, Y., Mu, R., Fraser, A. R., Pitman, N., Kurowska-Stolarska, M., McKenzie, A. N. J., McInnes, I. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801898105 · Cited by 464 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundKurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., Komai-Koma, M., Pitman, N., Li, Y., McKenzie, A. N. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4780 · Cited by 460
Imai, Y., Yasuda, K., Sakaguchi, Y., Haneda, T., Mizutani, H., Yoshimoto, T., Nakanishi, K., & Yamanishi, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307321110 · Cited by 431 · cited 1×
“IL-33 overexpression in the skin leads to an AD-like phenotype with infiltration of ILC2, mast cells, and eosinophils (14).”
BackgroundPastorelli, L., Garg, R. R., Hoang, S. B., Spina, L., Mattioli, B., Scarpa, M., Fiocchi, C., Vecchi, M., & Pizarro, T. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912678107 · Cited by 415 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundWedell-Neergaard, A.-S., Lang Lehrskov, L., Christensen, R. H., Legaard, G. E., Dorph, E., Larsen, M. K., Launbo, N., Fagerlind, S. R., Seide, S. K., Nymand, S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.007 · Cited by 403
Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13599 · Cited by 395
Silverberg, J. I., Garg, N. K., Paller, A. S., Fishbein, A. B., & Zee, P. C. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.325 · Cited by 340
Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.059 · Cited by 328
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation
Cohen, E. S., Scott, I. C., Majithiya, J. B., Rapley, L., Kemp, B. P., England, E., Rees, D. G., Overed-Sayer, C. L., Woods, J., Bond, N. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9327 · Cited by 270
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy
Verri, W. A., Souto, F. O., Vieira, S. M., Almeida, S. C. L., Fukada, S. Y., Xu, D., Alves-Filho, J. C., Cunha, T. M., Guerrero, A. T. G., Mattos-Guimaraes, R. B., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122655 · Cited by 263
Developments in therapy with monoclonal antibodies and related proteins
Shepard, H. M., Phillips, G. L., Thanos, C. D., & Feldmann, M. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-220 · Cited by 248 · cited 1×
“Targeted cytokine pathway intervention has been associated with enormous therapeutic advance (1).”
BackgroundSkin-Derived TSLP Triggers Progression from Epidermal-Barrier Defects to Asthma
Demehri, S., Morimoto, M., Holtzman, M. J., & Kopan, R. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000067 · Cited by 226
Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma
Liu, X., Li, M., Wu, Y., Zhou, Y., Zeng, L., & Huang, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.008 · Cited by 219 · cited 1×
“Multiple anti-IL33 antibodies have been developed and reported in mouse disease models (41-44).”
BackgroundWerfel, T., Morita, A., Grewe, M., Renz, H., Wahn, U., Krutmann, J., & Kapp, A. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12331164 · Cited by 217 · cited 1×
“IFNγ has been implicated in the pathogenesis of chronic AD (29, 30).”
BackgroundLingel, A., Weiss, T. M., Niebuhr, M., Pan, B., Appleton, B. A., Wiesmann, C., Bazan, J. F., & Fairbrother, W. J. (2009) · Structure · doi:10.1016/j.str.2009.08.009 · Cited by 212 · cited 1×
“This may reflect differential binding affinity or neutralization capacity of the sST2 compared with etokimab; for example, it is of note that the affinity of etokimab for IL-33 is very high [Kd (dissociation constant), 1 pM], whereas that for sST2 is 4 nM (28).”
BackgroundStructure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma
Verstraete, K., Peelman, F., Braun, H., Lopez, J., Van Rompaey, D., Dansercoer, A., Vandenberghe, I., Pauwels, K., Tavernier, J., Lambrecht, B. N., et al. (2017) · Nature Communications · doi:10.1038/ncomms14937 · Cited by 190 · cited 1×
“Several targeted systemic therapies are now emerging on the basis of the growing understanding of the involvement of type 2 immune polarization in atopic pathology (35).”
BackgroundThe dual nature of TH17 cells: shifting the focus to function
O'Connor, W., Zenewicz, L. A., & Flavell, R. A. (2010) · Nature Immunology · doi:10.1038/ni.1882 · Cited by 179
IL‐33 induces skin inflammation with mast cell and neutrophil activation
Hueber, A. J., Alves‐Filho, J. C., Asquith, D. L., Michels, C., Millar, N. L., Reilly, J. H., Graham, G. J., Liew, F. Y., Miller, A. M., & McInnes, I. B. (2011) · European Journal of Immunology · doi:10.1002/eji.201041360 · Cited by 167 · cited 1×
“Direct administration of IL-33 to murine skin leads to an infiltration of mast cells and neutrophils (16).”
BackgroundMechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis
Rebane, A., Zimmermann, M., Aab, A., Baurecht, H., Koreck, A., Karelson, M., Abram, K., Metsalu, T., Pihlap, M., Meyer, N., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.020 · Cited by 162
A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
Smith, D., Helgason, H., Sulem, P., Bjornsdottir, U. S., Lim, A. C., Sveinbjornsson, G., Hasegawa, H., Brown, M., Ketchem, R. R., Gavala, M., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006659 · Cited by 139 · cited 2×
“Eosinophil reduction in the blood of etokimabtreated patients further supports the broad effects of IL-33 inhibition, as predicted by genetic analysis of IL-33 loss of function in humans (15).”
BackgroundBlockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma
Lee, H., Rhee, C. K., Kang, J. Y., Byun, J. H., Choi, J. Y., Kim, S. J., Kim, Y. K., Kwon, S. S., & Lee, S. Y. (2014) · Experimental Lung Research · doi:10.3109/01902148.2013.870261 · Cited by 129
IL-33 exacerbates liver sterile inflammation by amplifying neutrophil extracellular trap formation
Yazdani, H. O., Chen, H.-W., Tohme, S., Tai, S., van der Windt, D. J., Loughran, P., Rosborough, B. R., Sud, V., Beer-Stolz, D., Turnquist, H. R., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.010 · Cited by 127 · cited 1×
“IL-33 also drives neutrophil migration to sites of infection (17, 18) and contributes to their activation (19, 20).”
BackgroundChoy, D. F., Hsu, D. K., Seshasayee, D., Fung, M. A., Modrusan, Z., Martin, F., Liu, F.-T., & Arron, J. R. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.044 · Cited by 125 · cited 1×
“Although marked elevation of skin neutrophils is not a typical conspicuous feature of AD (31), there is evidence that they may nevertheless contribute to the inflammatory process (32, 33), particularly during acute disease if secondary infection is present (31).”
BackgroundAnti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitis
Kim, Y. H., Yang, T. Y., Park, C. ‐., Ahn, S., Son, B.-K., Kim, J. H., Lim, D. H., & Jang, T. Y. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02735.x · Cited by 112
Xu, J., Guardado, J., Hoffman, R., Xu, H., Namas, R., Vodovotz, Y., Xu, L., Ramadan, M., Brown, J., Turnquist, H. R., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002365 · Cited by 93 · cited 1×
“IL-33 also drives neutrophil migration to sites of infection (17, 18), and contributes to their activation (19, 20).”
BackgroundFilaggrin inhibits generation of CD1a neolipid antigens by house dust mite–derived phospholipase
Jarrett, R., Salio, M., Lloyd-Lavery, A., Subramaniam, S., Bourgeois, E., Archer, C., Cheung, K. L., Hardman, C., Chandler, D., Salimi, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6833 · Cited by 92
Self-citationEpidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis
Indra, A. K. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.814881 · Cited by 87
Interleukin-33, friend and foe in type-2 immune responses
Hardman, C. S., & Ogg, G. S. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.004 · Cited by 83 · cited 4×
“Altered gene expression, use of a decoy receptor, and posttranslational modifications (for example, proteolytic processing and oxidation) all contribute to regulation of the IL-33 pathway (5, 6).”
BackgroundInfluentialSelf-citationLangeveld-Wildschut, E. G., Thepen, T., Biharia, I. C., van Reijsen, F. C., DEVRIESA, I., Bruijnzeel, P. L. B., & Bruijnzeel-Koomen, C. A. F. M. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)80186-2 · Cited by 81
Peng, G., Mu, Z., Cui, L., Liu, P., Wang, Y., Wu, W., & Han, X. (2017) · Inflammation · doi:10.1007/s10753-017-0673-7 · Cited by 75
IL-33 promotes Staphylococcus aureus-infected wound healing in mice
Yin, H., Li, X., Hu, S., Liu, T., Yuan, B., Ni, Q., Lan, F., Luo, X., Gu, H., & Zheng, F. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.07.008 · Cited by 58 · cited 3×
“IL-33 is known to modulate the inhibitory effects of bacterial infection on the neutrophil IL-8 receptor CXCR2 in animal models, but whether IL-33 can modulate IL-8 effects in human inflammation in vivo has not been studied, nor whether there is an impact of IL-33 on the other known IL-8 receptor, CXCR1 (17, 18, 22).”
BackgroundDhingra, N., Suárez-Fariñas, M., Fuentes-Duculan, J., Gittler, J. K., Shemer, A., Raz, A., Fischetti, V. A., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.043 · Cited by 52
Lan, F., Yuan, B., Liu, T., Luo, X., Huang, P., Liu, Y., Dai, L., & Yin, H. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.004 · Cited by 45 · cited 4×
“IL-33 is known to modulate the inhibitory effects of bacterial infection on the neutrophil IL-8 receptor CXCR2 in animal models, but whether IL-33 can modulate IL-8 effects in human inflammation in vivo has not been studied, nor whether there is an impact of IL-33 on the other known IL-8 receptor, CXCR1 (17, 18, 22).”
BackgroundInfluential
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Cayrol, C., & Girard, J.-P. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155891 · Cited by 322
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Metadata
- Authors
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G.
- Affiliations
- University of Oxford (GB)
- MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
- AnaptysBio, Inc. (United States) (US)
- Corresponding author
- Ogg, Graham
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-10-23
- Volume
- 11
- Issue
- 515
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2979421310
- Cited by
- 250
- References
- 46
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 38 · 2023: 31 · 2022: 48 · 2021: 50 · 2020: 37 · 2019: 1
- FWCI
- 34.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MCUU_0008/5)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, neutrophil migration, CXCR1, interleukin-8, eosinophils, skin inflammation, Eczema Area and Severity Index
- MeSH terms
- Interleukin-33, Antibodies, Monoclonal, Cell Movement, Dermatitis, Atopic, Eczema, Humans, Inflammation, Neutrophils, Skin, Interleukin-12, Receptors, Interleukin-8A, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.